Skip to content

Study supports recommendation that pregnancy be avoided in women taking ponatinib
Study finds ropeginterferon alfa-2b is ‘superior’ 2nd-line treatment for essential thrombocythemia
Longer-term follow-up demonstrates efficacy of nemtabrutinib for refractory FL
Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’
FELIX post-hoc data reinforce obe-cel durability

Join SOHO

Follow Us :

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Cellular Therapy

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Leukemia

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Lymphoma

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Multiple Myeloma

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Myelodysplastic Syndromes

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

June 15, 2025

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

SOHO Insider Hem/Onc Library Cellular Therapy

Cellular Therapy

3D rendering of genetically modified cells expressing chimeric antigen receptor for CAR Tcell therapy. Concept Biotechnology, Genetic Engineering, Cancer Immunotherapy, Medical Illustration

Cellular Therapy T-Cell Lymphoma

CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma

by Leah Sherwood
December 5, 2024
0 Comments

Approved

Cellular Therapy Mantle Cell Lymphoma

FDA approves liso-cel for relapsed or refractory MCL

by Leah Sherwood
June 6, 2024
0 Comments

1
2

Top Categories

$FDA approves liso-cel for relapsed or refractory MCL$

Cellular Therapy

12

$FDA approves liso-cel for relapsed or refractory MCL$

Leukemia

41

$FDA approves liso-cel for relapsed or refractory MCL$

Lymphoma

38

$FDA approves liso-cel for relapsed or refractory MCL$

Multiple Myeloma

28

$FDA approves liso-cel for relapsed or refractory MCL$

Myelodysplastic Syndromes

13

$FDA approves liso-cel for relapsed or refractory MCL$

Myeloproliferative Neoplasms

9

POPULAR NEWS

Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Neoplasms , News , Society Updates

Abstract submissions now open for SOHO 2025

February 14, 2025

MyeloMatch, NCI

Leukemia , Acute Myeloid Leukemia , Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

January 3, 2025

Imatinib

66th American Society of Hematology Annual Meeting & Exposition , Leukemia

Asciminib benefit-risk profile bests other TKIs in CML

December 10, 2024

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Categories

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Cellular Therapy

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Leukemia

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Lymphoma

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Multiple Myeloma

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Myelodysplastic Syndromes

$CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma$

Myeloproliferative Neoplasms

Subscribe

Recent Posts

pregnant woman's belly with fingers heart symbol

Study supports recommendation that pregnancy be avoided in women taking ponatinib

options

Study finds ropeginterferon alfa-2b is ‘superior’ 2nd-line treatment for essential thrombocythemia

Molecular structure of cancer cells under microscope, realistic macro indoor part of body.

Longer-term follow-up demonstrates efficacy of nemtabrutinib for refractory FL

Copyright © 2025 Society of Hematologic Oncology, All rights reserved.